Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab’s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Pharmacol
Päätekijät: Mazorra, Zaima, Lavastida, Anabel, Concha-Benavente, Fernando, Valdés, Anet, Srivastava, Raghvendra M., García-Bates, Tatiana M., Hechavarría, Esperanza, González, Zuyen, González, Amnely, Lugiollo, Martha, Cuevas, Iván, Frómeta, Carlos, Mestre, Braulio F., Barroso, Maria C., Crombet, Tania, Ferris, Robert L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2017
Aiheet:
Pharmacology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5474456/
https://ncbi.nlm.nih.gov/pubmed/28674498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00382
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia